Novo Nordisk A/S (NYSE:NVO) Hits New 52-Week High on Analyst Upgrade

Novo Nordisk A/S (NYSE:NVO)’s stock price hit a new 52-week high during mid-day trading on Monday after Argus raised their price target on the stock from $125.00 to $160.00. Argus currently has a buy rating on the stock. Novo Nordisk A/S traded as high as $143.90 and last traded at $143.86, with a volume of 2580873 shares changing hands. The stock had previously closed at $142.88.

Other research analysts have also recently issued research reports about the company. BMO Capital Markets began coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective on the stock. The Goldman Sachs Group began coverage on Novo Nordisk A/S in a research report on Thursday, May 30th. They issued a “buy” rating and a $156.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $145.67.

Institutional Investors Weigh In On Novo Nordisk A/S

Several institutional investors and hedge funds have recently bought and sold shares of the business. Jump Financial LLC bought a new position in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $387,000. Barclays PLC increased its position in Novo Nordisk A/S by 28.5% during the 3rd quarter. Barclays PLC now owns 17,694 shares of the company’s stock valued at $1,609,000 after buying an additional 3,926 shares in the last quarter. New York State Common Retirement Fund increased its position in Novo Nordisk A/S by 100.0% during the 3rd quarter. New York State Common Retirement Fund now owns 58,906 shares of the company’s stock valued at $5,357,000 after buying an additional 29,453 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Novo Nordisk A/S by 245.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 68,477 shares of the company’s stock valued at $6,227,000 after buying an additional 48,678 shares in the last quarter. Finally, UBS Group AG increased its position in Novo Nordisk A/S by 159.6% during the 3rd quarter. UBS Group AG now owns 627,390 shares of the company’s stock valued at $57,055,000 after buying an additional 385,675 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 0.5 %

The firm has a market cap of $644.41 billion, a P/E ratio of 48.79, a price-to-earnings-growth ratio of 1.48 and a beta of 0.41. The stock has a fifty day simple moving average of $129.73 and a 200 day simple moving average of $119.22. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.06. The business had revenue of $9.52 billion during the quarter, compared to analyst estimates of $9.23 billion. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. On average, research analysts expect that Novo Nordisk A/S will post 3.42 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.